Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3409
$0.00341.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -96.88% | -89.76% | -80.98% | -78.55% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -96.88% | -89.76% | -80.98% | -78.55% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -96.88% | -89.76% | -80.98% | -78.55% | -- |
| SG&A Expenses | 20.25% | -19.67% | -9.56% | -9.56% | -10.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.64% | -53.44% | -46.77% | -29.89% | -19.28% |
| Operating Income | 43.59% | 52.84% | 46.31% | 29.26% | 20.86% |
| Income Before Tax | 65.79% | 53.06% | 45.15% | 27.97% | 18.23% |
| Income Tax Expenses | 118.88% | 73.90% | 42.29% | 36.55% | 38.15% |
| Earnings from Continuing Operations | 57.62% | 50.29% | 45.63% | 26.34% | 13.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.62% | 50.29% | 45.63% | 26.34% | 13.96% |
| EBIT | 43.59% | 52.84% | 46.31% | 29.26% | 20.86% |
| EBITDA | 43.56% | 52.80% | 46.30% | 29.25% | 20.86% |
| EPS Basic | 86.34% | 80.33% | 62.27% | 39.11% | 23.28% |
| Normalized Basic EPS | 87.01% | 78.41% | 62.21% | 41.19% | 28.08% |
| EPS Diluted | 86.34% | 80.33% | 62.27% | 39.11% | 23.28% |
| Normalized Diluted EPS | 87.01% | 78.41% | 62.21% | 41.19% | 28.08% |
| Average Basic Shares Outstanding | 5,655.11% | 330.25% | 82.33% | 44.23% | 21.02% |
| Average Diluted Shares Outstanding | 5,655.11% | 330.25% | 82.33% | 44.23% | 21.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | 0.54% | 0.32% | 0.13% |